Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | HTR2A | P28223 | 7/20 | 0.48 |
| ▸ | DRD3 | P35462 | 7/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15971536 | 0.86 | HTR2C (0.73) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL15971496 | 0.85 | HTR2C (0.71) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL28038474 | 0.83 | HTR2C (0.69) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL3679735 | 0.83 | HTR2C (0.69) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL1601087 | 0.83 | HTR2C (0.69) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL15971545 | 0.83 | HTR2C (0.64) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL30297584 | 0.82 | HTR2C (1.00) | HTR2C | |
| SCHEMBL1026755 | 0.82 | HTR2C (1.00) | HTR2C | |
| SCHEMBL3062978 | 0.81 | AKR1C3 (0.53) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL15971543 | 0.78 | HTR2C (0.62) | HTR2CDRD2HTR2ADRD3PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008152394-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | claimed |
| US-20170029441-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029441-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029441-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| EP-3092242-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-11-16 | — | — | EP | disclosed |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-2958920-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015104254-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-16 | — | — | WO | disclosed |
| WO-2014128093-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014128093-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029441-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | VEGFA, PGF, FLT1 | HTR2C 1926/4885DRD2 2688/4885HTR2A 1908/4885 |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | CCNI, F12, MKI67 | HTR2C 2049/4885DRD2 1422/4885HTR2A 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.